Targeting TNF to EDB delayed tumor growth in teratocarcinoma models compared to untargeted cytokine, and the anti-cancer effect was amplified when co-administered with melphalan or an EDB-specific IL-12 immunocytokine [24,84]. Here, TNF is linked to cancer.